Bioventus Inc. develops and commercializes medical device products for active healing, pain treatment, musculoskeletal care and surgical applications. The company organizes its portfolio around Pain Treatments, Restorative Therapies and Surgical Solutions, including products such as peripheral nerve stimulation devices, bone graft substitutes, ultrasonics, hyaluronic acid injections and ultrasound-based fracture healing therapies.
Recurring Bioventus news covers quarterly and annual results, financial guidance, revenue trends across its product areas and geographic markets, cash flow and margin performance, healthcare conference presentations, portfolio updates and regulatory developments affecting products such as Peripheral Nerve Stimulation offerings.
Bioventus has initiated its initial public offering (IPO) of 7,350,000 Class A common stock shares, pricing expected between $16.00 and $18.00 each. The underwriters may purchase an additional 1,102,500 shares for overallotments. The shares will trade on Nasdaq under the symbol 'BVS.' Morgan Stanley, J.P. Morgan, and Goldman Sachs are leading the offering, while a registration statement has been filed with the SEC but is not yet effective. This IPO aims to fund Bioventus' mission to provide clinically proven products that promote healing and enhance active lifestyles.